Treat to target in systemic lupus erythematosus: a commentary

Manuel F. Ugarte-Gil, Paula I. Burgos, Graciela S. Alarcón

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Treat to target (T2T) strategies have proved to be useful in several chronic disorders, including Rheumatoid Arthritis. In systemic lupus erythematosus (SLE), T2T strategy has been proposed in order to control disease activity, improve health-related quality of life, and reduce morbidity and mortality. Remission would be the main target, but a low disease activity state (LDAS) could be an acceptable alternative. However, due to SLE protean manifestations, the operational definitions of both remission and LDAS are still in progress. The definitions of these targets, remission and LDAS, should include a validated disease activity index, the treatments allowed, and the minimum length of time the target should be maintained. Furthermore, achieving these targets should result in better disease outcomes such as reducing damage accrual. This review addresses the current state regarding these possible targets in SLE and the impact of achieving them in intermediate and long-term outcomes of this disease.

Original languageEnglish
Pages (from-to)1903-1907
Number of pages5
JournalClinical Rheumatology
Issue number8
StatePublished - 1 Aug 2016


  • Outcome
  • Remission
  • Systemic lupus erythematosus
  • Therapy


Dive into the research topics of 'Treat to target in systemic lupus erythematosus: a commentary'. Together they form a unique fingerprint.

Cite this